Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial

Background There are limited options currently recommended in National Institute for Health and Care Excellence guidelines for the treatment of bipolar depression. Pramipexole has been shown to improve mood symptoms in two small pilot studies in such patients. Objectives Primary: to evaluate the cli...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Hamish McAllister-Williams, Nicola Goudie, Lumbini Azim, Victoria Bartle, Michael Berger, Chrissie Butcher, Thomas Chadwick, Emily Clare, Paul Courtney, Lyndsey Dixon, Nichola Duffelen, Tony Fouweather, William Gann, John Geddes, Sumeet Gupta, Beth Hall, Timea Helter, Paul Hindmarch, Eva-Maria Holstein, Ward Lawrence, Phil Mawson, Iain McKinnon, Adam Milne, Aisling Molloy, Abigail Moore, Richard Morriss, Anisha Nakulan, Judit Simon, Daniel Smith, Bryony Stokes-Crossley, Paul Stokes, Andrew Swain, Zoë Walmsley, Christopher Weetman, Allan H Young, Stuart Watson
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	NIHR Journals Library 2025-05-01
سلاسل:	Health Technology Assessment
الموضوعات:	pramipexole treatment-resistant bipolar depression bipolar disorder bipolar depression depression adults randomised controlled trial placebo controlled multisite treatment outcome quality of life economic evaluation qualitative ppi psychiatry health economics
الوصول للمادة أونلاين:	https://doi.org/10.3310/HBFC1953
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!